Related Experiment Videos
Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Probing Benchmark Models of Hidden-Sector Dark Matter with DAMIC-M.
Physical review letters·2025
Assessment of food waste hydrochar as a soil amendment: Effects on soil properties, plant growth and stress response.
Waste management (New York, N.Y.)·2025
Search for Daily Modulation of MeV Dark Matter Signals with DAMIC-M.
Physical review letters·2024
First Constraints from DAMIC-M on Sub-GeV Dark-Matter Particles Interacting with Electrons.
Physical review letters·2023
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Thymic radiation is associated with worse outcomes in patients with NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026